RAD51C C135Y
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C C135Y sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C S163R
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C S163R sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D108G
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D108G sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C A155E
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C A155E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C K131I
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C K131I sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C V156D
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C V156D sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G114V
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G114V sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G150E
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G150E sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R237P
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R237P sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C L138F
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C L138F sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T132R
|
osteosarcoma
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T132R sensitized RAD51C-null osteosarcoma cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell survival (PMID: 37253112).
|
37253112
|
RAD51C G153D
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G153D sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G150E
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G150E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T132I
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T132I sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T336P
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T336P sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G306R
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G306R sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G153D
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G153D sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T132R
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T132R sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G114R
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G114R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R312W
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R312W sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D159Y
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D159Y sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D348V
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D348V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C K131I
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C K131I sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C S163R
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C S163R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C V140E
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C V140E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D159A
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D159A sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G130R
|
osteosarcoma
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G130R sensitized RAD51C-null osteosarcoma cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell survival (PMID: 37253112).
|
37253112
|
RAD51C A155E
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C A155E sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C Q133E
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C Q133E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R168G
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R168G sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D242N
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D242N sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G125V
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G125V sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D159Y
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D159Y sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G302V
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G302V sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R237P
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R237P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G114V
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G114V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C V156D
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C V156D sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D108G
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D108G sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R168G
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R168G sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G302V
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G302V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G130R
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G130R sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C A279P
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C A279P sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C Q133E
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C Q133E sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T132R
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T132R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G162E
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G162E sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C L27P
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C L27P sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C L27P
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C L27P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D348V
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D348V sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R312W
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R312W sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C D159A
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D159A sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C L138F
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C L138F sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G130R
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G130R sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T336P
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T336P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C V140E
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C V140E sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C R168G
|
osteosarcoma
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C R168G sensitized RAD51C-null osteosarcoma cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell survival (PMID: 37253112).
|
37253112
|
RAD51C D242N
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C D242N sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T102I
|
Advanced Solid Tumor
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T102I sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T102I
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T102I sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C A279P
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C A279P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C K131I
|
osteosarcoma
|
sensitive
|
Olaparib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C K131I sensitized RAD51C-null osteosarcoma cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell survival (PMID: 37253112).
|
37253112
|
RAD51C G162E
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G162E sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C T132I
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C T132I sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|
RAD51C G125V
|
Advanced Solid Tumor
|
sensitive
|
Cisplatin
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the expression of RAD51C G125V sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112).
|
37253112
|